Incidence and Prevalence of Idiopathic Inflammatory Myopathies in Korea: a Nationwide Population-based Study

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2019 Mar 6

PMID 30833879

Citations 13

Authors

Soo-Kyung Cho

Hyoungyoung Kim

Jisun Myung

Eunwoo Nam

Sun-Young Jung

Eun Jin Jang

Dae-Hyun Yoo

Yoon-Kyoung Sung

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to estimate the incidence and prevalence of idiopathic inflammatory myopathies (IIM) and associated comorbidities in Korea from 2006 to 2015.

Methods: IIM between 2004 to 2015 were identified using the Korean National Health Insurance Service medical claim database. The case definition required more than one visit based on diagnostic codes including juvenile dermatomyositis (JDM), dermatomyositis (DM), or polymyositis (PM) and registration in the Individual Copayment Beneficiaries Program (ICBP) for rare and intractable diseases. IIM patients with a disease-free period of 24 months before the index date were defined as incident cases. The Elixhauser comorbidity score was calculated.

Results: Using the base case definition, 1,150 prevalent patients with IIM (117 JDM, 521 DM, 512 PM) were recorded in 2006 and 2,210 (130 JDM, 1,101 DM, 869 PM) in 2015. The prevalence was estimated at 2.3-4.0 (0.9-1.2 for JDM, 1.2-2.7 for DM, 1.4-2.1 for PM)/100,000 person-year (PY). We identified 218 incident cases of IIM in 2006 (18 JDM, 98 DM, 102 PM) and 191 cases (7 JDM, 83 DM, 101 PM) in 2015. The incidence was estimated at 2.9-5.2 (0.7-1.9 for JDM, 1.8-4.0 for DM, 1.6-3.0 for PM)/1,000,000 PY. The mean age (± standard deviation) of prevalent patients with IIM was 51.2 (± 16.9) years, and the percentage of women was 72.1%. More than two-thirds of patients (70.7%) had more than two comorbidities. Twenty percent of patients had interstitial lung diseases.

Conclusion: In Korea, the incidence and prevalence of IIM were 2.9-5.2/1,000,000 PY and 2.3-4.0/100,000 PY, respectively.

Citing Articles

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE.

Jiang W, Jia W, Dong C Thromb J. 2024; 22(1):34.

PMID: 38576023 PMC: 10993540. DOI: 10.1186/s12959-024-00599-3.

Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan.

Hu Q, Huang K, Goh C, Tsuchiya Y, Liu Y, Qiu H Sci Rep. 2023; 13(1):17172.

PMID: 37821555 PMC: 10567809. DOI: 10.1038/s41598-023-44092-9.

Epidemiology of the idiopathic inflammatory myopathies.

Khoo T, Lilleker J, Thong B, Leclair V, Lamb J, Chinoy H Nat Rev Rheumatol. 2023; 19(11):695-712.

PMID: 37803078 DOI: 10.1038/s41584-023-01033-0.

Myositis interstitial lung disease and autoantibodies.

Chaudhry S, Christopher-Stine L Front Med (Lausanne). 2023; 10:1117071.

PMID: 37384043 PMC: 10296774. DOI: 10.3389/fmed.2023.1117071.

Low serum level of citrullinated histone H3 in patients with dermatomyositis.

Wang W, Peng W, Wu S J Clin Lab Anal. 2023; 37(6):e24876.

PMID: 37003600 PMC: 10156100. DOI: 10.1002/jcla.24876.

References

Hengstman G, van Venrooij W, Vencovsky J, Moutsopoulos H, van Engelen B . The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis. 2000; 59(2):141-2. PMC: 1753065. DOI: 10.1136/ard.59.2.141. View

Bohan A, Peter J . Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8):403-7. DOI: 10.1056/NEJM197502202920807. View

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

Michaud K, Wolfe F . Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007; 21(5):885-906. DOI: 10.1016/j.berh.2007.06.002. View

Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H . Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011; 38(8):1636-43. DOI: 10.3899/jrheum.101002. View

Kuo C, See L, Yu K, Chou I, Chang H, Chiou M . Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. 2011; 165(6):1273-9. DOI: 10.1111/j.1365-2133.2011.10595.x. View

Cho S, Sung Y, Choi C, Bae S . Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int. 2011; 32(12):3851-6. DOI: 10.1007/s00296-011-2312-1. View

Furst D, Amato A, Iorga S, Gajria K, Fernandes A . Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012; 45(5):676-83. DOI: 10.1002/mus.23302. View

Oddis C, Conte C, Steen V, Medsger Jr T . Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990; 17(10):1329-34. View

10.

Barnabe C, Joseph L, Belisle P, Labrecque J, Barr S, Fritzler M . Prevalence of autoimmune inflammatory myopathy in the first nations population of Alberta, Canada. Arthritis Care Res (Hoboken). 2012; 64(11):1715-9. DOI: 10.1002/acr.21743. View

11.

Smoyer-Tomic K, Amato A, Fernandes A . Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. 2012; 13:103. PMC: 3480956. DOI: 10.1186/1471-2474-13-103. View

12.

Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P . The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int. 2012; 33(4):965-71. DOI: 10.1007/s00296-012-2489-y. View

13.

Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch M . Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2013; 73(1):62-8. PMC: 3888623. DOI: 10.1136/annrheumdis-2013-204223. View

14.

Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H . Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod Rheumatol. 2013; 24(3):477-80. DOI: 10.3109/14397595.2013.844308. View

15.

Dobloug C, Garen T, Bitter H, Stjarne J, Stenseth G, Grovle L . Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2014; 74(8):1551-6. DOI: 10.1136/annrheumdis-2013-205127. View

16.

Meyer A, Meyer N, Schaeffer M, Gottenberg J, Geny B, Sibilia J . Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2014; 54(1):50-63. DOI: 10.1093/rheumatology/keu289. View

17.

England B, Sayles H, Mikuls T, Johnson D, Michaud K . Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken). 2014; 67(6):865-72. DOI: 10.1002/acr.22456. View

18.

Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen A . Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. Lung. 2016; 194(5):733-7. PMC: 11678787. DOI: 10.1007/s00408-016-9896-x. View

19.

Svensson J, Arkema E, Lundberg I, Holmqvist M . Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology (Oxford). 2017; 56(5):802-810. DOI: 10.1093/rheumatology/kew503. View

20.

Dobloug G, Svensson J, Lundberg I, Holmqvist M . Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis. 2017; 77(1):40-47. DOI: 10.1136/annrheumdis-2017-211402. View